J R Perry

Summary

Affiliation: Sunnybrook Health Sciences Centre
Country: Canada

Publications

  1. doi request reprint Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach
    James R Perry
    Crolla Family Brain Tumour Research Unit, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada
    Cancer 113:2152-7. 2008
  2. pmc Thromboembolic disease in patients with high-grade glioma
    James R Perry
    Division of Neurology and Odette Cancer Centre, University of Toronto, Canada
    Neuro Oncol 14:iv73-80. 2012
  3. doi request reprint Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents
    James R Perry
    Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
    Curr Opin Neurol 23:592-6. 2010
  4. doi request reprint PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
    J R Perry
    Division of Neurology, Sunnybrook Health Science Centre, Toronto Ontario, Canada
    J Thromb Haemost 8:1959-65. 2010
  5. doi request reprint Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study
    James R Perry
    Division of Neurology, Sunnybrook Health Sciences Center, Room A402, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5
    J Clin Oncol 28:2051-7. 2010
  6. doi request reprint A citywide prehospital protocol increases access to stroke thrombolysis in Toronto
    David J Gladstone
    North and East GTA Ontario Regional Stroke Centre and Division of Neurology, Department of Medicine, and Brain Sciences Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Stroke 40:3841-4. 2009
  7. ncbi request reprint Oligodendrogliomas: clinical and genetic correlations
    J R Perry
    Division of Neurology, Department of Medicine, University of Toronto, Sunnybrook and Women s College Health Science Centre, Room A 442, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Curr Opin Neurol 14:705-10. 2001
  8. ncbi request reprint Bony metastases of anaplastic oligodendroglioma respond to temozolomide
    Tara Morrison
    Division of Neurology, Crolla Family Brain Tumour Research Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Can J Neurol Sci 31:102-8. 2004
  9. ncbi request reprint Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 78:295-302. 2006
  10. ncbi request reprint Glioma therapies: how to tell which work?
    James R Perry
    J Clin Oncol 21:3547-9. 2003

Detail Information

Publications10

  1. doi request reprint Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach
    James R Perry
    Crolla Family Brain Tumour Research Unit, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada
    Cancer 113:2152-7. 2008
    ..Despite advances in first-line therapy, there are few data on treatment of glioblastoma multiforme (GBM) at recurrence. Temozolomide (TMZ) is well tolerated and may have activity despite prior TMZ exposure if novel dose schedules are used...
  2. pmc Thromboembolic disease in patients with high-grade glioma
    James R Perry
    Division of Neurology and Odette Cancer Centre, University of Toronto, Canada
    Neuro Oncol 14:iv73-80. 2012
    ....
  3. doi request reprint Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents
    James R Perry
    Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
    Curr Opin Neurol 23:592-6. 2010
    ..Recent advances in the cause, prevention, and treatment of VTE in brain tumor patients in the era of antiangiogenic therapy are reviewed...
  4. doi request reprint PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
    J R Perry
    Division of Neurology, Sunnybrook Health Science Centre, Toronto Ontario, Canada
    J Thromb Haemost 8:1959-65. 2010
    ..Venous thromboembolism (VTE) occurs in 20-30% of patients with malignant glioma per year of survival. We tested the efficacy of long-term dalteparin low-molecular-weight heparin (LMWH) for prevention of VTE in these patients...
  5. doi request reprint Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study
    James R Perry
    Division of Neurology, Sunnybrook Health Sciences Center, Room A402, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5
    J Clin Oncol 28:2051-7. 2010
    ..Patients who experience progression during the first six cycles of conventional adjuvant TMZ therapy or after a treatment-free interval get the most benefit from therapy...
  6. doi request reprint A citywide prehospital protocol increases access to stroke thrombolysis in Toronto
    David J Gladstone
    North and East GTA Ontario Regional Stroke Centre and Division of Neurology, Department of Medicine, and Brain Sciences Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Stroke 40:3841-4. 2009
    ..This report describes the initial impact of the activation protocol at our regional stroke center...
  7. ncbi request reprint Oligodendrogliomas: clinical and genetic correlations
    J R Perry
    Division of Neurology, Department of Medicine, University of Toronto, Sunnybrook and Women s College Health Science Centre, Room A 442, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Curr Opin Neurol 14:705-10. 2001
    ..This review will focus upon the past year of advances in the area of clinical-molecular genetic predictors of glioma behaviour and highlight the importance of these advances in everyday clinical practice...
  8. ncbi request reprint Bony metastases of anaplastic oligodendroglioma respond to temozolomide
    Tara Morrison
    Division of Neurology, Crolla Family Brain Tumour Research Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Can J Neurol Sci 31:102-8. 2004
    ..Fewer than 30 cases of oligodendroglioma or anaplastic oligodendroglioma metastatic to bone are reported in the literature. Prolonged survival even with therapy is uncommon...
  9. ncbi request reprint Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 78:295-302. 2006
    ..Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas...
  10. ncbi request reprint Glioma therapies: how to tell which work?
    James R Perry
    J Clin Oncol 21:3547-9. 2003